GARDASIL®9 (Human Papillomavirus 9-Valent Vaccine, Recombinant 9vHPV) in prevention of Cervical Cancer in Adolescent Females.

Authors

Rose-Marie P. Leriche, Lynchburg UniversityFollow

Specialty

DMSc

Advisor

Dr. Reid

Abstract

ABSTRACT

Purpose: This study aims to prove the significance of early GARDASIL®9 vaccination in adolescent females before exposure to HPV and targeting all ethnic groups in HPV awareness.

Methods: A prospective, single-arm, open-label, non-randomized, Phase IIa trial of a nonavalent prophylactic HPV vaccine in assessing the immunogenicity of a prime and deferred-booster dosing schedule among 9-11-year-old girls and boys. In conducting a PubMed literature search with the search term GARDASIL®9 vaccines, adolescent females, and HPV, twelve pertinent articles were retrieved and served as the basis for this clinical case report.

Results: The authors prove that a single dose of GARDASIL®9 would cause continual and steady serological responses for up to 24 months to all nine HPV virus types. Early vaccination of the monovalent GARDASIL®9 vaccines administered at ages 9 to 11 in adolescent males and females before exposure to HPV infection will reduce HPV infection and cervical cancer burden. They surveyed Hispanic, Caucasian, and African American participants and found African Americans were most affected by HPV. In addition, African American parents were not really in line with HPV vaccination for their children. The groups have some knowledge about HPV, HPV vaccination, and cervical cancer but not in-depth knowledge about these topics.

Conclusions: A single dose of HPV vaccination GARDASIL®9 proves a great result in preventing infection that most commonly leads to cervical cancer and lessens the costs of HPV vaccination in the United States (U.S.) and worldwide. Furthermore, targeting educational efforts among all ethnic groups is essential to improve HPV awareness and associated preventive health measures to avoid HPV-related morbidity and mortality.

Recommended Citation

Leriche RP. GARDASIL®9 (Human Papillomavirus 9-Valent Vaccine, Recombinant 9vHPV) in prevention of Cervical Cancer in Adolescent Females.. University of Lynchburg DMSc Doctoral Project Assignment Repository. 2021; 3(4).